Lucio Iannone
Biotech Investor
Cambridge, Massachusetts
Overview
Work Experience
Head of Health Venture Investments (VP)
2021 - Current
* Identify, develop, drive and manage the portfolio of biotech ventures through to proof of concept (POC) including defining and shaping the setup of the ventures, developing the rationale and business case for investing in the selected technologies * Develop the network and follow scientific developments in selected areas * lead the venture team in deals and due diligence; * Drive and oversee the start-up of ventures and monitors/reports the progress of ventures * Train and manage junior team members * Review and make recommendations on go/no-go decision points
Sr Director of Venture Investments
2017 - 2021
• Developing rationale and business case for investing in selected technologies •Leading the sourcing, screening, and mentoring of companies with game-changing science •Conducting due diligence and supports deal execution •Supporting start-up of ventures, day-to-day management, performance management and strategic decisions of the ventures •Supporting the setup of the new organization •Monitoring progress of ventures •Supporting the venture in daily operations •Preparing and facilitating venture milestones •Establish and maintain relationships with healthcare innovators, both in entrepreneurial and academic settings
Board Member
2022
Affini-T is pioneering engineered TCR T cell therapies with cutting-edge synthetic biology and gene editing enhancements to target oncogenic driver mutations that exclusively strike all tumor cells at the core of their biology.
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.
Raised $175,000,000.00 from Parker Institute for Cancer Immunotherapy, Fred Hutchinson, Agent Capital, Alexandria Venture Investments, Humboldt Fund, Vida Ventures, Erasca Ventures, Leaps by Bayer and Catalio Capital Management.
Board Member
2019
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.
Board Member
2022
Paratus Sciences is a start-up biotech company committed to improving human health and health security through an understanding of bat biology. We are focused on identifying and developing potential therapeutics for a myriad of diseases by unlocking the secrets of the bat genome.
Board Member
2019
Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers.
Immunitas Therapeutics is a single cell genomics-based drug discovery company that modulates oncology targets.
Raised $97,000,000.00 from M Ventures, Evotec, 120 Capital Management, NS Investment, BrightEdge Fund, Leaps by Bayer, Medical Excellence Capital, Longwood Fund, Ono Venture Investment and Novartis Venture Fund.
Board Member
2021
Mozart is developing CD8 T cell immune modulators for the treatment of autoimmune diseases. Founded on seminal work from leading scientists, Mozart is developing biologics to target a novel T cell network of pathogenic CD4 and cytolytic-regulatory CD8 T cells.
Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.
Raised $80,000,000.00 from Ono Venture Investment, UPMC Enterprises, Pfizer Venture Investments, AbbVie, ARCH Venture Partners, Leaps by Bayer, Alexandria Venture Investments, Eli Lilly, MRL Ventures Fund and Sofinnova Partners.
Board Member
2021
Deka has developed disease-specific Diakines™ that maximize patient benefits through improved pharmacokinetics/pharmacodynamics (PK/PD) function via targeted delivery of dual and complementary cytokines to affected tissues or cells.
Early stage biotechnology company
Raised $91,351,474.00 from MPM Capital, Echo Investment Capital, Leaps by Bayer, Alexandria Venture Investments, Lumira Ventures, Plains Ventures, John Mumm, Amana Investments, Viva BioInnovator and ATEM Capital Fund LP.
Board Observer
2023
Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence
Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.
Raised $251,400,000.00 from Nextech Invest, Piper Heartland Healthcare Capital, ARCH Venture Partners, RA Capital Management, Wellington Management, Surveyor Capital, Fidelity, Logos Capital, City Hill Ventures and Alexandria Venture Investments.
Board Observer
2022
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway
NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients.
Raised $122,500,000.00 from Leaps by Bayer, Invus, Arkin Holdings, Gordon Freeman, WTT Investment, Binney Street Capital, Sixty Degree Capital, Sanofi Ventures, MPM Capital and Catalio Capital Management.
Board Observer
2022
Cellino is on a mission to make personalized, autologous cell therapies accessible for patients. Stem cell-derived regenerative medicines are poised to cure some of the toughest diseases within this decade, including Parkinson’s, diabetes, and heart disease.
Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies.
Raised $122,500,002.00 from Advanced Research Projects Agency for Health.